Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System
Tianqi Liu, Ruonan Gao, Li Li, Bin Wu, Fengbo Wu
Topics & Concepts
TofacitinibMedicineRuxolitinibAdverse Event Reporting SystemAdverse effectJanus kinase inhibitorJanus kinaseInternal medicineConfidence intervalOdds ratioOncologyMyelofibrosisRheumatoid arthritisBone marrowCytokineMusculoskeletal synovial abnormalities and treatmentsDermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis